2020
Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon‐Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi D, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Molecular Oncology 2020, 14: 645-656. PMID: 31891442, PMCID: PMC7053235, DOI: 10.1002/1878-0261.12627.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmAntineoplastic AgentsCamptothecinCarcinoma, EndometrioidCell Adhesion MoleculesCell DifferentiationCell Line, TumorCell SurvivalEndometrial NeoplasmsFemaleHumansImmunoconjugatesImmunohistochemistryIrinotecanMiceMice, SCIDTissue Array AnalysisXenograft Model Antitumor AssaysConceptsAntibody-dependent cell cytotoxicityCell surface antigen 2EC cell linesSacituzumab govitecanTrop-2 expressionPrimary tumor cell linesTrop-2Xenograft modelAntigen 2Cell linesTumor cell linesCommon gynecologic malignancyFuture clinical trialsChromium release assaysParaffin-embedded tumorsTumor growth inhibitionSignificant bystander killingEC xenograftsGynecologic malignanciesEndometrial cancerEndometrial adenocarcinomaEndometrioid carcinoma tissuesPreclinical activityControl antibodyClinical trials
2019
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecologic Oncology 2019, 156: 430-438. PMID: 31839338, DOI: 10.1016/j.ygyno.2019.11.018.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCamptothecinCell Adhesion MoleculesCell Line, TumorCystadenocarcinoma, SerousFemaleFlow CytometryHumansImmunoconjugatesImmunohistochemistryMiceMice, SCIDMolecular Targeted TherapyRandom AllocationTissue Array AnalysisUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaCell surface antigen 2Sacituzumab govitecanTrop-2 expressionTrop-2Serous carcinomaAntigen 2Advanced/recurrent diseasePrimary uterine serous carcinomaResistant human tumorsSignificant bystander killingUSC patientsUSC xenograftsRecurrent diseaseClinical responseEndometrial cancerAggressive variantPoor prognosisPreclinical activityPrimary tumorIntravenous administrationClinical developmentUSC samplesActive metaboliteSN-38
2016
Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors
Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, Brouwer-Visser J, Cossio MJ, Whitney KD, Yu H, Gunter MJ, Huang GS. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes & Control 2016, 27: 737-748. PMID: 27125830, PMCID: PMC4870288, DOI: 10.1007/s10552-016-0751-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDiabetes MellitusEndometrial NeoplasmsEndometriumEstrogen Receptor alphaEstrogensFemaleGene ExpressionGonadal Steroid HormonesHumansImmunohistochemistryInsulinInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedParityPhosphoproteinsPostmenopausePremenopausePTEN PhosphohydrolaseReal-Time Polymerase Chain ReactionReceptor, IGF Type 1Receptor, InsulinReceptors, ProgesteroneReceptors, SomatomedinRisk FactorsRNA, MessengerConceptsInsulin-like growth factorEndometrial cancer risk factorsCancer risk factorsPostmenopausal womenRisk factorsEndometrial tissueInsulin/insulin-like growth factorRegular nonsteroidal anti-inflammatory drug useNonsteroidal anti-inflammatory drug usePhosphorylated insulin-like growth factorEstrogen receptor-positive tissuesAnti-inflammatory drug useNon-diabetic womenProtein levelsReceptor-positive tissuesNormal endometrial tissuesHigher IGFBP1OC usePostmenopausal endometriumBenign indicationsProgesterone receptorQuantitative real-time PCRHormone axesIGFBP3 expressionHuman endometrium
2010
Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma
Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO. Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcoma. American Journal Of Obstetrics And Gynecology 2010, 203: 242.e1-242.e5. PMID: 20605134, PMCID: PMC2933955, DOI: 10.1016/j.ajog.2010.04.046.Peer-Reviewed Original ResearchConceptsUterine carcinosarcomaProgesterone receptorDisease progressionEpithelial expressionG protein-coupled receptor 30Early-stage carcinosarcomaAdvanced stage diseaseExpression of GPR30Expression levelsWilcoxon rank sum testRank sum testLower ERalphaReceptor 30PR expressionNormal endometriumEstrogen receptorGPR30Positive cellsCarcinosarcomaLogistic regressionERbetaSum testERalphaAlternative ERsTissue sections
2006
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB, McDaid HM. Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice. Clinical Cancer Research 2006, 12: 298-304. PMID: 16397055, PMCID: PMC4039036, DOI: 10.1158/1078-0432.ccr-05-0229.Peer-Reviewed Original ResearchMeSH KeywordsAlkanesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCaspasesCell CycleCell Line, TumorDrug SynergismEnzyme ActivationFemaleHumansImmunohistochemistryLactonesMiceNeovascularization, PathologicOvarian NeoplasmsPaclitaxelPlatelet Endothelial Cell Adhesion Molecule-1PyronesXenograft Model Antitumor AssaysConceptsXenograft-bearing miceOvarian carcinomaTumor regressionCarcinoma cellsHuman ovarian cancer cellsOvarian carcinoma xenograftsOvarian cancer cellsCombination index methodOvarian carcinoma cellsCell cycle distributionTaxol efficacyCarcinoma xenograftsCD31 immunohistochemistryDrug combinationsImmunohistochemical analysisAnimal modelsSingle agentAntiangiogenic effectsLow dosesVivo modelNotable toxicityAntitumor efficacyDrug concentrationsCycle distributionMice